Research Profile

Patrick Harrison

Biography

Gene Editing for Research and Therapy

The research focus of the Harrison Lab is the development of gene editing to study and potentially treat genetic disorders such as cystic fibrosis (CF), cystinosis and atopic dermatitis. 

What is CRISPR gene editing?  

CRISPR gene editing is a technique that enables the sequence of DNA of a living cell to be precisely changed, and has at least three major biomedical applications:

  • First, this ability to precisely change a DNA sequence within a cell allows researchers to learn how particular DNA sequences control the normal structure and functions of individual cells.
  • Second, it enables us to learn of how certain mutations in the DNA sequence, either acquired or inherited, can cause more than 100 different types of cancer or over 7,000 genetic disorders.
  • Third, gene editing could be developed as the basis for a potential treatments for many of these diseases, such as cystic fibrosis (CF), sickle-cell anaemia and cystinosis.  
How do you precisely edit a DNA sequence, in a live cell?  

Editing a DNA sequence is somewhat similar to editing a text document on a computer:
 

  • The first step is to find (ctrl F) the precise DNA sequence to be changed then to cut it out (ctrl X). With CRISPR gene editing, a guide RNA molecule in combination with the Cas9 nuclease is used to find the target sequence and cut the DNA at that point. 
  • The next step in text editing is to copy (ctrl C) a few letters or a word from a dictionary and paste (ctrl V) them into the correct place to change the meaning of a sentence. In cells, we don’t use a dictionary, rather a synthetic piece of DNA with the desired sequence is inserted into the target cells. 
  • The synthetic DNA contains the new DNA sequences as well as some sequence similarity (or homology) to the target region of the selected gene which helps it to be correctly copied and pasted (or ligated) into the cut site generated by Cas9/guideRNA. The end result is genomic DNA with a sequence corresponding to that in the synthetic DNA. 
  • In summary, the Cas9/guide RNA makes a targeted break in the genome, and the synthetic DNA provides the new information. The process is mediated in cells by a naturally occurring DNA repair mechanism known as homology-directed repair (HDR).    

The Gene Editor's Keyboard
 https://twitter.com/P_T_Harrison/status/909809309609005056

When was gene editing discovered

Gene editing technology was first described in the early 1980s. The development of this technique (usually referred to as gene targeting at that time) and its subsequent use to study physiological and disease processes, led to the award of the Nobel Prize for Physiology or Medicine in 2007:

https://www.nobelprize.org/nobel_prizes/medicine/laureates/2007

Despite this technology, efficient editing in human cells wasn’t described until 2005 following the development of a synthetic type of proteins known as programmable zinc finger nucleases (ZFNs). The ZFNs enabled researchers to optimise the first step of gene editing, a targeted break in the DNA close to the target region of the gene to be modified.

A couple of years later, a second gene editing system was reported, the Tal-effector nucleases (TALENs) and cells edited with these reagents were approved for use by the US FDA on 30th August 2017  in the treatment of a very specific type of cancer known as B-cell Acute Lymphoblastic Leukaemia:

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm

Despite the availability of these two techniques, it wasn’t until 2012 and the first publication on CRISPR gene editing that the field became to a much wider audience, including our own lab.
   

How are we using CRISPR to understand Cystic Fibrosis?
 

We have used both ZFN and CRISPR to correct the DNA sequence in cells which contains the most common CF mutation known as F508del (or p.Phe508del). Many other groups have also used CRISPR, TALENs and other reagents to do similar experiments. Whilst these experiments establish “proof-of-principle” for correction of CF-causing mutations, a common challenge is the relatively low level of editing cells, typically 1-2%, which is regarded as insufficient for therapeutic benefit; the precise level of editing required to treat lung disease in a person with CF is not yet known, but 20-30% is possibly a realistic goal.

Another challenge is that there are at least 281 known CF-causing mutations (see www.cftr2.org), but HDR typically repairs just one mutation at a time.
  To address efficiency, we have used a simpler approach known as NHEJ to edit a small group of CF-causing mutations known as deep intronic mutations. There are at least five different types of this mutation, and we’ve recently established proof-of-principle for correction of three of them:

http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0184009

Whilst our experiments have shown this approach is much more efficient than HDR which we used in our early experiments, this approach will still only correct a small number of disease-causing mutations. Thus, we are now focusing much of our efforts on an approach known as HITI to correct many different mutations at the same time. The HITI technique was only described for the first time in November 2016, but we’ve very recently secured funds from the CF Foundation and the CF Trust  to start some experiments using this approach for CF mutations.

Optimisation of editing is just the start of the journey in the development of a new therapeutic approach to CF. Subsequent steps will include the safe and efficient delivery of the editing machinery to ultimately determine if gene editing technology can be used to successfully treat CF lung disease for every person with CF, regardless of their CFTR mutations.
   

Review Articles

European Biopharmaceutical Review (Autumn 2016)
http://www.samedanltd.com/magazine/12/issue/260/article/4436

Paediatric Pulmonology (Oct 2016)
https://www.ncbi.nlm.nih.gov/pubmed/27662105

Human Genetics (Sept 2016)
https://www.ncbi.nlm.nih.gov/pubmed/27325484

Irish Times (Feb 2016) 
http://www.irishtimes.com/news/science/gene-editing-where-do-you-draw-the-line-1.2511209

Research Interests

Gene Repair

The research focus of the Harrison Lab is the development of gene editing to repair disease-causing mutations in the human genome. The current focus is the use of CRISPR gene editing as research tools and potential therapeutic agents for genetic diseases including Cystic Fibrosis, Cystinosis, and Atopic Dermatitis.

2017 onwards - CRISPR NHEJ and HITI for Cystic Fibrosis and Atopic Dermatitis

The current focus is on NHEJ based methods. Our most recent published study showed effective excision of CF-causing deep intronic mutations (Sanz et al., 2017), but the major focus now is the use of HITI to correct multiple mutations with a single donor and Cas9/gRNA combination. This work is supported by grants from CF Foundation Therapeutics (USA) and CF Trust (UK). The lab is also a member of the CF Trust's Strategic Research Centre for Gene Editing.

We have set up two new collaborations, one with Dusko Ilic in King's College London to edit iPS cells to study atopic dermatitis (funded by the LEO foundation) and with Carlos Farinha in Lisbon to create novel cell lines to study rare CF mutations (part funded by CF Foundation). 

2013 to 2016 - CRISPR HDR for Cystic Fibrosis

In 2013, the lab starting using the CRISPR Cas9/gRNA system for gene editing to correct the F508del mutation by HDR (Hollywood et al., 2016) with grants from CF Foundation Therapeutics (USA) and CF Trust (UK). 

The lab has funded collaborative projects with Alan Davidson and Jennifer Hollywood in Auckland (funded by Cystinosis Ireland and Health Research Board), and Isabelle Sermet in Paris (funded by HRB).

2005 to 2012 - Application of ZFN HDR to cystic fibrosis

Since 2005, my lab has been working on the production of ZFNs to target the most common gene defect in patients with cystic fibrosis. This work was started by a PhD student, Rowan Flynn, and is currently under further investigation by Ciaran Lee and Jennifer Hollywoord. Using an in vitro system, we developed ZFNs which can target and correct the F508del mutation in the cftr gene http://online.liebertpub.com/doi/abs/10.1089/biores.2012.0218

2008 to 2012 - Application of ZFN HDR to cystinosis

Cystinosis is a rare genetic disorder affecting less than 10 individuals in Ireland. The disease which is a multisystem disorder invariably leads to kidney failure. The gene defect was characterised in 1999, and Dr. Harrison and Dr. Scallan were recently been awarded funding from Cystinosis Ireland (www.cystinosis.ie) and the HRB (www.hrb.ie), as well as the Cystinosis Research Foundation (www.natalieswish.org) to study the applicability of ZFN HDR technology,  virus vector delivery and Tale nuclease gene repair. This work has been conducted by Katrin Kaschig and Ciaran Lee.

2001 to 2007 - Molecular Physiology

Between 2001 and 2007, the Department hosted five 10-day residential workshop to provide training for physiologists in molecular biological techniques (Harrison, 2004). The workshop was sponsored by the Physiological Society and the Wellcome Trust, and offered training in experimental procedures in molecular physiology, including the handling of DNA and RNA, sub-cloning, restriction enzyme digests, the use of siRNA technology, western blots, RT-PCR, site-directed mutagenesis and transfection techniques. During this time over 80 physiologists at PhD or post-doctoral level attended these workshops. Further details of other courses organised by the physiological society can be found at www.physoc.org. In 2010, the Department hosted two shorter workshops for physiologists, again sponsored by the Physiological Society.


Research Grants

 ProjectFunding
Body
Start DateEnd DateAward
Science Foundation of Ireland01-FEB-1631-JUL-16€3,000.00
Splicing mutationsForeign Research Institute17-NOV-1416-NOV-16€53,476.00
Modelling cystinosis with human stem cells and the therapeutic potential of aspartic acidHealth Research Board01-NOV-1430-OCT-17€295,000.00
Cystic Fibrosis Foundation Therapeutics CRISPR Knock-Out of Class 1 CF Splicing Mutations.Foreign Research Institute01-OCT-1430-SEP-17€162,902.00
Permanent correction of 80% of Disease causing Mutations in Human CF cells.Foreign Research Institute01-OCT-1330-SEP-14€59,000.00
Cystinosis Ireland "In viro gene repair - towards a cure for cystinosis.Irish Funded Research01-JUN-1331-MAY-14€10,000.00
Gene repair Conference.Health Research Board01-DEC-1230-JUN-14€14,000.00

Publications

Peer Reviewed Journals

 YearPublication
(2016)'Analysis of gene repair tracts from Cas9/gRNA double-stranded breaks in the human CFTR gene'
Hollywood, JA,Lee, CM,Scallan, MF,Harrison, PT (2016) 'Analysis of gene repair tracts from Cas9/gRNA double-stranded breaks in the human CFTR gene'. Scientific Reports, 6 [DOI] [Details]
(2016)'Genetic medicines for CF: Hype versus reality'
Alton EW;Boyd AC;Davies JC;Gill DR;Griesenbach U;Harrison PT;Henig N;Higgins T;Hyde SC;Innes JA;Korman MS; (2016) 'Genetic medicines for CF: Hype versus reality'. Pediatric Pulmonology, 51 (S44) [DOI] [Details]
(2016)'Impact of gene editing on the study of cystic fibrosis'
Harrison PT;Sanz DJ;Hollywood JA; (2016) 'Impact of gene editing on the study of cystic fibrosis'. Human Genetics, 135 (9) [DOI] [Details]
(2012)'Correction of the ΔF508 mutation in the CFTR gene by zinc finger nuclease homology-directed repair'
Lee, CM, Flynn, R, Hollywood, JA, Scallan, MF and Harrison, PT (2012) 'Correction of the ΔF508 mutation in the CFTR gene by zinc finger nuclease homology-directed repair'. BioResearch Open Access, 1 (2):99-108   [DOI] [Details]
(2011)'E47 retroviral rescue of intrinsic B cell defects in senescent mice'
Landin, Ana Marie,Frasca, Daniela,Harrison, Patrick,Scallan, Martina,Riley, Richard L.,Blomberg, Bonnie B.; (2011) 'E47 retroviral rescue of intrinsic B cell defects in senescent mice'. Aging Cell,   [Details]
(2010)'AAV2-mediated in vivo immune gene therapy of solid tumours'
Collins, S. A.,Buhles, A.,Scallan, M. F.,Harrison, P. T.,O'Hanlon, D. M.,O'Sullivan, G. C.,Tangney, M.; (2010) 'AAV2-mediated in vivo immune gene therapy of solid tumours'. Genetic vaccines and therapy, 8   [Details]
(2010)'Effects of GDF5 overexpression on embryonic rat dopaminergic neurones in vitro and in vivo'
O’Sullivan, D.B., Harrison, P.T., Sullivan, A.M. (2010) 'Effects of GDF5 overexpression on embryonic rat dopaminergic neurones in vitro and in vivo'. Journal of Neural Transmission, 117 (5):559-572 [DOI] [Details]
(2008)'Application of Gene Therapy in Diabetes Care (review)'
Harrison PT ; (2008) 'Application of Gene Therapy in Diabetes Care (review)'. Infect Disord Drug Targets, 8 (2):129-133 [Details]
(2008)'Viral vectors in cancer immunotherapy: which vector for which strategy?'
Collins SA, Guinn BA, Harrison PT, Scallan MF, O'Sullivan GC, Tangney M; (2008) 'Viral vectors in cancer immunotherapy: which vector for which strategy?'. Current Gene Therapy, 8 (2):66-78 [Details]
(2004)'FcgammaRIIa expression with FcgammaRI results in C-reactive protein- and IgG-mediated phagocytosis. J Leukoc Biol'
Bodman-Smith, K. B.,Gregory, R. E.,Harrison, P. T.,Raynes, J. G.; (2004) 'FcgammaRIIa expression with FcgammaRI results in C-reactive protein- and IgG-mediated phagocytosis. J Leukoc Biol'. J Leukoc Biol, 75 (6):1029-35   [Details]
(2002)'C-reactive protein-mediated phagocytosis and phospholipase D signalling through the high-affinity receptor for immunoglobulin G (FcgammaRI). Immunology'
Bodman-Smith, K. B.,Melendez, A. J.,Campbell, I.,Harrison, P. T.,Allen, J. M.,Raynes, J. G.; (2002) 'C-reactive protein-mediated phagocytosis and phospholipase D signalling through the high-affinity receptor for immunoglobulin G (FcgammaRI). Immunology'. Immunology, 107 (2):252-60 [Details]
(1999)'Novel cell lines for the analysis of preprotachykinin A gene expression identify a repressor domain 3' of the major transcriptional start site'
Fiskerstrand CE, Newey P, Ebrahimi B, Gerrard L, Harrison P, McGregor GP, Quinn JP; (1999) 'Novel cell lines for the analysis of preprotachykinin A gene expression identify a repressor domain 3' of the major transcriptional start site'. The Biochemical Journal, 341 ( Pt 3) :847-852 [Details]
(1999)'Neuronal-specific and nerve growth factor-inducible expression directed by the preprotachykinin-A promoter delivered by an adeno-associated virus vector. Neuroscience'
Harrison, P. T.,Dalziel, R. G.,Ditchfield, N. A.,Quinn, J. P.; (1999) 'Neuronal-specific and nerve growth factor-inducible expression directed by the preprotachykinin-A promoter delivered by an adeno-associated virus vector. Neuroscience'. Neuroscience, 94 (3):997-1003 [Details]
(1998)'High affinity IgG binding by FcgammaRI (CD64) is modulated by two distinct IgSF domains and the transmembrane domain of the receptor. Protein Eng'
Harrison, P. T.,Allen, J. M.; (1998) 'High affinity IgG binding by FcgammaRI (CD64) is modulated by two distinct IgSF domains and the transmembrane domain of the receptor. Protein Eng'. Protein Eng, 11 (3):225-32 [Details]
(1998)'Use of GPI-anchored proteins to study biomolecular interactions by surface plasmon resonance. FEBS Lett'
Harrison, P. T.,Campbell, I. W.,Allen, J. M.; (1998) 'Use of GPI-anchored proteins to study biomolecular interactions by surface plasmon resonance. FEBS Lett'. FEBS Lett, 422 (3):301-6 [Details]
(1998)'Lysosomal routing of Fc gamma RI from early endosomes requires recruitment of tyrosine kinases. Immunology'
Norman, J. C.,Harrison, P. T.,Davis, W.,Floto, R. A.,Allen, J. M.; (1998) 'Lysosomal routing of Fc gamma RI from early endosomes requires recruitment of tyrosine kinases. Immunology'. Immunology, 94 (1):48-55 [Details]
(1996)'Protein:protein interactions in the lipid bilayer (review)'
Harrison PT. ; (1996) 'Protein:protein interactions in the lipid bilayer (review)'. Mol Membr Biol, 13 (`2):67-79 [Details]
(1995)'Two distinct regions of FC gamma RI initiate separate signalling pathways involved in endocytosis and phagocytosis. EMBO J'
Davis, W.,Harrison, P. T.,Hutchinson, M. J.,Allen, J. M.; (1995) 'Two distinct regions of FC gamma RI initiate separate signalling pathways involved in endocytosis and phagocytosis. EMBO J'. EMBO J, 14 (3):432-41 [Details]
(1995)'The interaction between human Fc gamma RI and the gamma-chain is mediated solely via the 21 amino acid transmembrane domain of Fc gamma RI. Mol Membr Biol'
Harrison, P. T.,Bjorkhaug, L.,Hutchinson, M. J.,Allen, J. M.; (1995) 'The interaction between human Fc gamma RI and the gamma-chain is mediated solely via the 21 amino acid transmembrane domain of Fc gamma RI. Mol Membr Biol'. Mol Membr Biol, 12 (4):309-12 [Details]
(1995)'Site-directed mutagenesis of varicella-zoster virus thymidylate synthase. Analysis of two highly conserved regions of the enzyme. Eur J Biochem'
Harrison, P. T.,Scott, J. E.,Hutchinson, M. J.,Thompson, R.; (1995) 'Site-directed mutagenesis of varicella-zoster virus thymidylate synthase. Analysis of two highly conserved regions of the enzyme. Eur J Biochem'. Eur J Biochem, 230 (2):511-6 [Details]
(1995)'Fc gamma receptor-mediated phagocytosis requires tyrosine kinase activity and is ligand independent. Eur J Immunol'
Hutchinson, M. J.,Harrison, P. T.,Floto, R. A.,Allen, J. M.; (1995) 'Fc gamma receptor-mediated phagocytosis requires tyrosine kinase activity and is ligand independent. Eur J Immunol'. Eur J Immunol, 25 (2):481-7 [Details]
(1994)'Binding of monomeric immunoglobulin G triggers Fc gamma RI-mediated endocytosis. J Biol Chem'
Harrison, P. T.,Davis, W.,Norman, J. C.,Hockaday, A. R.,Allen, J. M.; (1994) 'Binding of monomeric immunoglobulin G triggers Fc gamma RI-mediated endocytosis. J Biol Chem'. J Biol Chem, 269 (39):24396-402 [Details]
(1994)'A convenient method for the construction and expression of GPI-anchored proteins. Nucleic Acids Res'
Harrison, P. T.,Hutchinson, M. J.,Allen, J. M.; (1994) 'A convenient method for the construction and expression of GPI-anchored proteins. Nucleic Acids Res'. Nucleic Acids Res, 22 (18):3813-4 [Details]
(1991)'Evolution of herpesvirus thymidine kinases from cellular deoxycytidine kinase. J Gen Virol'
Harrison, P. T.,Thompson, R.,Davison, A. J.; (1991) 'Evolution of herpesvirus thymidine kinases from cellular deoxycytidine kinase. J Gen Virol'. J Gen Virol, 72 ( Pt 10) :2583-6 [Details]

Conference Publications

 YearPublication
(2014)11th European Cystic Fibrosis Society Meeting, Malta
Hollywood, JA, Lee, CM, Scallan, MF and Harrison, PT. (2014) Strategy to correct >80% of CF-causing mutations using CRISPR/Cas9 and mini-gene constructs 11th European Cystic Fibrosis Society Meeting, Malta [Details]
(2007)15th Annual Congress of the European Society of Gene and Cell Therapy
Collins S., Harrison PT, Scallan MF; (2007) Adeno-associated virus-mediated gene therapy for cancer . In: Human Gene Therapy 18 (10) eds. 15th Annual Congress of the European Society of Gene and Cell Therapy , pp.999-999 [Details]
(2005)Viral vectors to deliver neurotrophin genes to a rat model of Parkinson's disease
Kelly, TA, Harrison, PT, Scallan, MF and Sullivan, AM; (2005) Viral vectors to deliver neurotrophin genes to a rat model of Parkinson's disease Viral vectors to deliver neurotrophin genes to a rat model of Parkinson's disease , pp.529-530 [Details]
(2005)16th International Congress on Parkinson’s Disease and Related Disorders, Berlin, Germany
Kelly, T.A., Harrison, P.T., Scallan, M.F., Sullivan, A.M. (2005) Lentiviral-mediated delivery of growth/differentiation factor-5 attenuates parkinsonian symptoms in the rat . In: Parkinsonism & Related Disorders Volume 11, Supplement 2 eds. 16th International Congress on Parkinson’s Disease and Related Disorders, Berlin, Germany Berlin, [Details]
(2005)Physiological Society meeting, Bristol, UK
Flynn R, O’Sullivan D, Sullivan, A.M., Harrison P. (2005) Use of pCEP4 Vector for Simple and Rapid Establishment of Stable Cell-Lines and Long-Term Gene Expression Physiological Society meeting, Bristol, UK [Details]
(2005)Society for Neuroscience meeting, Washington, USA
O’Sullivan, D.B., Harrison, P.T., Nolan, Y.M., Sullivan, A.M. (2005) Prevention of apoptosis in cultured dopaminergic neurons by GDNF and GDF5 . In: Soc. Neurosci. Abs. 899.12 eds. Society for Neuroscience meeting, Washington, USA Washington DC, USA, , 12-NOV-05 - 16-NOV-05 , pp.889.12-* [Details]
(2004)Anatomical Society of Great Britain and Ireland Summer Meeting 2004, Cork, Ireland
O’Sullivan, D.B., Harrison, P.T., Sullivan, A.M. (2004) Rat ventral mesencephalic cultures transfected with a plasmid expressing growth/differentiation factor 5 exhibit improved dopaminergic neuronal survival . In: J. Anat. 205 (6) eds. Anatomical Society of Great Britain and Ireland Summer Meeting 2004, Cork, Ireland [Details]
(2004)Physiological Society meeting, Bristol, UK
Kelly T.A., Harrison P.T., Scallan M.F., Sullivan, A.M. (2004) Viral vectors to deliver neurotrophin genes to a rat model of Parkinson’s disease Physiological Society meeting, Bristol, UK [Details]
(2004)4th Forum of European Neuroscience Lisbon Portugal
O’Sullivan, D.B., Sullivan, A.M., Harrison, P.T. (2004) Establishment of neurotrophin-expressing dopaminergic cells for transplantation in Parkinson’s disease . In: FENS Abstr. Vol.2, A053.17 eds. 4th Forum of European Neuroscience Lisbon Portugal [Details]
(2004)Anatomical Society of Great Britain and Ireland Summer Meeting 2004, Cork, Ireland
Kelly, T.A., Harrison, P.T., Scallan, M.F., Sullivan, A.M. (2004) Viral vectors to deliver neurotrophin genes to a rat model of Parkinson’s disease . In: J. Anat. 205 (6) eds. Anatomical Society of Great Britain and Ireland Summer Meeting 2004, Cork, Ireland [Details]
(2013)22nd European Gene and Cell Therapy Conference, Madrid, Spain
Hollywood, JA, Lee, CM1, Kaschig, K., Artemiuk, P., Scallan, MF and Harrison, PT. (2013) Gene editing of CFTR and CTNS mutations using ZFNs and CRISPr/Cas-9 guide RNAs 22nd European Gene and Cell Therapy Conference, Madrid, Spain [Details]
(2013)Gene editing of CFTR and CTNS mutations using ZFNs and CRISPr/Cas-9 guide RNAs
Hollywood, JA,Lee, CM,Kaschig, K,Flynn, R,Artemiuk, P,Scallan, MF,Harrison, PT (2013) HUMAN GENE THERAPY Gene editing of CFTR and CTNS mutations using ZFNs and CRISPr/Cas-9 guide RNAs , pp.87-87 [Details]
(2011)European Society of Gene and Cell Therapy, Brighton UK
Lee, CM,Scallan, MF,Harrison, PT (2011) The development of zinc finger nucleases to target mutations in the cystinosin gene using the rapid OPEN screening method European Society of Gene and Cell Therapy, Brighton UK [Details]
(2011)European Society of Gene and Cell Therapy, Brighton UK
Kaschig, K,Lee, CM,Hollywood, JA,Scallan, MF,Harrison, PT (2011) Kaschig, K,Lee, CM,Hollywood, JA,Scallan, MF,Harrison, PT European Society of Gene and Cell Therapy, Brighton UK [Details]
(2011)Cystinosis gene repair: A functional assay to detect restoration of the CTNS gene via homology-directed repair using Zinc finger nucleases
Kaschig, K,Lee, CM,Hollywood, JA,Scallan, MF,Harrison, PT (2011) HUMAN GENE THERAPY Cystinosis gene repair: A functional assay to detect restoration of the CTNS gene via homology-directed repair using Zinc finger nucleases , pp.49-49 [Details]
(2011)The development of zinc finger nucleases to target mutations in the cystinosin gene using the rapid OPEN screening method
Lee, CM,Scallan, MF,Harrison, PT (2011) HUMAN GENE THERAPY The development of zinc finger nucleases to target mutations in the cystinosin gene using the rapid OPEN screening method , pp.50-50 [Details]

Book Chapters

 YearPublication
(2011)'Comparison of DNA Delivery and Expression Using Frequently Used Delivery Methods'
Collins SA, Morrissey D, Rajendran S, Casey G, Scallan MF, Harrison PT, O'Sullivan GC, Tangney M. ; (2011) 'Comparison of DNA Delivery and Expression Using Frequently Used Delivery Methods' In: Gene Therapy - developments and future perspectives. Croatia: InTech. [Details]
(2009)'Gene Therapy and Individualised Medicine'
Harrison, PT, Flynn, R, Lee CM ; (2009) 'Gene Therapy and Individualised Medicine' In: Predictive Diagnostics and Personalized Treatment. Nova Science Publishers, Inc. [Details]

Professional Activities

Professional Associations

 AssociationFunctionFrom / To
European Association of Predictive, Preventive and Personalised Medicine (EPMA; www.epmanet.eu) Ireland’s representative for EPMA (2008-2010)01-JAN-08 / 31-DEC-10
Physiological Society - Member Member since 200001-JAN-00 /
Physiological Society Finance Committee Member01-JAN-02 / 31-DEC-05
Physiological Society Council Member and Trustee01-JAN-04 / 31-DEC-06
Ligand Xpress (SC177459) Company Director01-JUL-98 / 31-DEC-00

Conference Contributions

 YearPublication
(2016)Physiological Society Gene Editing Workshop,
Harrison PT (2016) Beginners guide to Cpf1 and Cas9 Gene Editing. [Invited Lectures (Workshops)], Physiological Society Gene Editing Workshop, London, UK , 15-NOV-16. [Details]
(2016)Association of Clinical Biochemists Ireland,
Harrison, PT (2016) Z to A of Gene Editing. [Invited Lectures (Conference)], Association of Clinical Biochemists Ireland, Cork, Ireland , 11-NOV-16. [Details]
(2016)NACFC,
Harrison, PT (2016) CF Deep Intron Theratype Gene Editing. [Invited Lectures (Workshops)], NACFC, Orlando . [Details]
(2016)CFF: New Froniters,
Patrick Harrison (2016) Gene Editing for CF Therapy. [Chair Sessions at Symposia], CFF: New Froniters, Savannah, USA . [Details]
(2016)39th ECFS,
Patrick Harrison (2016) Novel Models for CF Gene Editing. [Invited Lectures (Conference)], 39th ECFS, Basel, Switzerland . [Details]
(2016)2nd Genetic Disorders UK,
Patrick Harrison (2016) Gene Editing, Cut, Correct, Cure?. [Keynote Speaker], 2nd Genetic Disorders UK, London, UK . [Details]
(2016)2nd Dublin Cystinosis Workshop,
Patrick Harrison (2016) Conference Organiser. [Conference Organising Committee Chairperson], 2nd Dublin Cystinosis Workshop, Dublin, Ireland . [Details]
(2016)2nd Dublin Cystinosis Workshop,
Patrick Harrison (2016) Gene Replacement Therapy for Cystinosis. [Invited Lectures (Conference)], 2nd Dublin Cystinosis Workshop, Dublin, Ireland . [Details]
(2016)Austrian Dermatological Society,
Patrick Harrison (2016) Cas9 gene editing for Skin disorders. [Invited Lectures (Conference)], Austrian Dermatological Society, Salzburg, Austria . [Details]
(2015)Oxford Global Gene Editing Conference,
Patrick Harrison (2015) Cas9 gene editing for CF. [Invited Lectures (Conference)], Oxford Global Gene Editing Conference, London, UK . [Details]
(2015)North American CF Conference,
Patrick Harrison (2015) Gene Editing Workshop. [Invited Lectures (Conference)], North American CF Conference, Phoenix USA , 28-OCT-15. [Details]
(2015)British Society of Gene and Cell Therapy,
Patrick Harrison (2015) CRISPR gene editing in metabolic disease. [Invited Lectures (Conference)], British Society of Gene and Cell Therapy, Glasgow, UK . [Details]
(2015)CFF: Pushing the Frontiers,
Patrick Harrison (2015) CRISPR gene KO for type I splicing mutations. [Invited Lectures (Conference)], CFF: Pushing the Frontiers, Washington DC, USA . [Details]
(2014)1st European Workshop on Cystinosis Research,
Harrison, PT (2014) Workshop. [Conference Organising Committee Chairperson], 1st European Workshop on Cystinosis Research, Dublin . [Details]
(2014)11th European Cystic Fibrosis Society Basic Science Conference,
Harrison, PT (2014) Symposium co-chair - CF modifier genes. [Chair Sessions at Symposia], 11th European Cystic Fibrosis Society Basic Science Conference, Malta . [Details]
(2014)1st European Workshop on Cystinosis Research,
Harrison, PT (2014) Invited Speaker - Gene Editing for Cystinosis. [Invited Lectures (Workshops)], 1st European Workshop on Cystinosis Research, Dublin . [Details]
(2012)35th European Cystic Fibrosis Conference, Dublin “Overview of Proteins involved in Membrane Trafficking”,
Harrison, PT (2012) Invited Speaker - Overview of Proteins involved in Membrane Trafficking. [Invited Lectures (Conference)], 35th European Cystic Fibrosis Conference, Dublin “Overview of Proteins involved in Membrane Trafficking”, Dublin . [Details]
(2012)35th European Cystic Fibrosis Society Clinical Conference,
Harrison, PT (2012) Symposium co-chair - CF Rescue Strategies. [Chair Sessions at Symposia], 35th European Cystic Fibrosis Society Clinical Conference, Dublin . [Details]

Other Activities

 Description

2014 - PhD External Examiner, Aberdeen

2014 - Poster Judge, UK Cystic Fibrosis Conference, Manchester

2012 - PhD External Examiner, Liverpool

2007 - PhD External Examiner, Cambridge

2006 - PhD External Examiner, Liverpool

2005 - Poster Judge, Young Physiologists’ Symposium, Physiological Society, Seville

2004 - Poster Judge, Physiological Society Conference, Cork

Committees

 CommitteeFunctionFrom / To
CK402 - Biological Sciences Member2012 /
College of Medicine and Health Executive Committee Member - representing School of Life Sciences2010 / 2011
Biological Sciences - UCC 2nd Biological Sciences BSc co-ordination2002 / 2009

Employment

 EmployerPositionFrom / To
University College Cork Senior Lecturer01-OCT-01 /
Cellular Physiology Research Unit, UCC Senior Research Fellow01-NOV-00 / 01-SEP-01
University of Glasgow Lecturer01-NOV-98 / 01-OCT-00
University of Edinburgh Post-Doc01-APR-97 / 01-OCT-98
Institute of Molecular Pathology, VIenna Post-Doc25-MAR-96 / 26-MAR-97
University of Glasgow Post-Doc01-OCT-94 / 24-MAR-96
University of Cambridge Post-Doc01-JAN-92 / 30-SEP-94

Education

 YearInstitutionQualificationSubject
1992University of Glasgow PHDVirology
1987University of Liverpool BSCBiochemistry

Consultancy

 ClientDescription
Enterprise Ireland
Grant Reviewer
Action Medical Research for Children (UK)
Grant Reviewer
Biological and Biomedical Science Research Council (UK)
Grant reviewer
Health Research Board
Grant Reviewer

Outreach Activities

 Description

2010 - Colaiste Choilm School - Seminar Speaker: Gene Delivery – The Science Behind Gene Therapy

2008 - Nurture Creche Cork - Kids Workshop Presenter - How do you build a human?

2005 - British Association Festival in Dublin - Seminar Speaker: Gene Delivery – The Science Behind Gene Therapy

2010 - Nurture Creche Cork - Kids Workshop Presenter - How do you build a human?

Journal Activities

 JournalRoleTo / From
Scientific Reports Referee-
Journal Of Cystic Fibrosis Referee-
Epma Journal Member of Editorial Board-
Molecular Therapy Referee-

Languages

 LanguageReadingWritingSpeaking
German BasicBasicFunctional
French FunctionalBasicFunctional

Teaching Activities

Teaching Interests

Recent Postgraduates

 Graduation YearStudent NameInstitutionDegree TypeThesis Title
2013Jennifer Hollywood PHDCystic fibrosis gene repair : correction of ΔF508 using ZFN and CRISPR/Cas9 guide RNA gene editing tools
2013Katrin Kaschig PHDZinc finger nuclease gene repair as a treatment for cystinosis
2013Ana Marie Landin PHDMolecular regulation of B cell deficiency with age : a study of E47 and Pax-5
2011Sarah Collins PHDAdeno-Associated virus vectors for cancer gene therapy
2010Ciaran Lee UCCPHDCystic fibrosis gene repair : development of zinc finger nucleases for homology directed repair of the CFTR

Modules Taught

 Term (ID))TitleLinkSubject
2018Cell and Epithelial Physiology PL2025Cell and Epithelial Physiology
2018Cell and Epithelial Physiology PL3005Cell and Epithelial Physiology
2018Literature Project on Genetics GN3002Literature Project on Genetics
2018Molecular and Cellular Physiology Techniques PL6001Molecular and Cellular Physiology Techniques

Contact details

Search profiles by name

Search profiles by topic

Physiology Department

Fiseolaíocht

Western Gateway Building Western Road University College Cork

Top